Onco Actu du 9 mars 2017

	3. Prévention
Experts call for increased efforts to prevent cancer [WUSTL] Strategies for cancer prevention are outlined March 9 in The New England Journal of Medicine by researchers from Washington University School of Medicine in St. Louis and the Harvard School of Public Health.
	3.1 Tabac
Smoking rates in the UK hit record low [Cancer Research UK] “It’s essential the Government finds sustainable funding for Stop Smoking Services and mass media quit campaigns, and publishes the Tobacco Control Strategy for England without further delay.”
	4. Dépistage, diagnostic et pronostic
Testing for Hepatitis C Virus Remains Low among Baby Boomers [ACS] Two years after recommendations, only a small percentage have been tested.
Few Boomers Get Hepatitis C Test Even Though It Can Save Lives [Dr. Len] Why is this important? Because if you do have hepatitis C you are at risk of dying from liver cancer and other diseases.
	4.5 Dép., diag. & prono. - Colorectal
I learned the hard way that colon cancer is on the rise among younger people [STAT] Perhaps it is time to revise these screening recommendations. How many more people must develop seemingly impossible cancers before we institute safer practices?
	5. Traitements
Mayo Clinic researchers identify therapy that shrinks tumors in patients with multiple myeloma [Mayo Clinic] The research highlights the importance of studying the effects of drugs not only on the tumor cells in a culture plate, but also on the interaction of the tumor cells with their own microenvironment. The finding that LCL161 is active against multiple myeloma suggests that similar drugs may have broader clinical activity than previously thought.
	5.10 Traitements - Essais
Trial Type and Time to Enrolling First Patient Linked to Slow Patient Accrual in Cancer Clinical Trials [AACR] Data showed that only 14 percent of the slow-accruing trials published at least one peer-reviewed paper, as opposed to 69 percent of the trials that accrued two or more participants per year.
Cancer treatments 'not being trialled in children' [BBC News] Since 2012, 62% of approved EU cancer drugs were not tested on under-18s. But cancer scientists say the rules should be changed so that adult cancer drugs have to be tested on children. They are also calling for the age limit for adult clinical trials to be lowered to include teenagers.
	5.12.2 Immunothérapies - CAR-T
Servier and Pfizer announce FDA clearance of IND application for UCART19 in Adult Relapsed/Refractory Acute Lymphoblastic Leukemia [Cellectis] Servier is sponsoring the CALM Phase 1 study on UCART19. In 2015, Servier acquired exclusive rights from Cellectis for UCART19, which is being co-developed by Servier and Pfizer.
	5.2 Pharma
Langer-backed cancer, fibrotic upstart XTuit takes on ex-Forum chief as CEO [FierceBiotech] Before joining XTuit, I spent the most considerable time with our founder, Dr. Rakesh Jain, of Mass General Hospital’s Edwin L. Steele Laboratory for Tumor Biology. Key aspects of XTuit’s unique approach were incubated in Dr. Jain’s lab, and he has incredible insights into cancer biology related to the microenvironment that are impressive and captured my attention and imagination.
Bristol-Myers Squibb Appoints Dr. Thomas J. Lynch, Jr., Executive Vice President and Chief Scientific Officer [BMS] Dr. Lynch said, “Throughout my career, I have been devoted to advancing oncology research, with a particular focus on lung cancer."
Under the gun after Opdivo setbacks, Bristol-Myers Squibb names a new chief scientist [EndPoints] Lynch spent 23 years at Massachusetts General Hospital, serving as chairman and chief executive officer of Massachusetts General Physicians Organization and as a member of the MGH Board from 2015 to 2017.
	5.4 Traitements - Economie
Do big R&D budgets justify US premium drug prices? No way, analysts scoff [EndPoints] That premium, they say, nets 15 companies $116 billion in extra annual revenue, compared to $76 billion in total research spending.
	6.10 Politiques
Show drugs work before selling them [Nature] Europe should beware too. Lower drug-quality requirements in the large US market could make firms that adhere to the higher standards in the European Union less competitive.
UK children with cancer could miss out on drug trials after Brexit, doctors warn [The Guardian] Leading doctors are warning that British children with cancer could suffer if they are no longer able to join Europe-wide trials of innovative new medicines as a result of the Brexit deal.
	6.10.1 Politiques (USA)
ASCO Raises Concerns about ACA Market Stabilization Proposal [ASCO] ASCO cautioned against implementing a provision in the proposal that would eliminate federal oversight of network adequacy for oncology care, since alternative methods of assessment may not require sufficient scrutiny or provide consistent, adequate access to care.
Statement from ASH President on Introduction of the Cancer Drug Parity Act [ASH] The American Society of Hematology applauds the efforts of Representatives Lance and Higgins to reduce this high cost burden on patients by seeking to provide parity in coverage between oral, self-administered, and IV cancer therapies.
	6.5 Médecines alternatives
Hallelujah! The mainstream press finally notices quackademic medicine! [Respectful Insolence] Nearly all the directors of integrative medicine programs interviewed reported that their patient volume has been growing. It just goes to show that many academic medical centers are more than willing to sell snake oil to attract patients. This is what skeptics are up against.
	6.7 DMP, Big Data & applis
Medical Community Urges Delay in Requiring 2015 CEHRT [ASCO] ASCO recently joined more than 100 medical specialty groups and state medical societies in signing an American Medical Association-led letter urging the Centers for Medicare & Medicaid Services (CMS) and Office of the National Coordinator for Health Information (ONC) to delay requiring 2015 Edition Certified Electronic Health Record Technology (CEHRT) until such technology is widely available—and no sooner than January 2019.
Leading Oncology Professional Societies Launch CancerLinQ® Ambassadors Program [ASCO] Collaboration will Enable On-the-Ground Engagement to CancerLinQ® Participants Nationwide.
	6.9 Controverses
DePinho Announces His Departure from Houston’s MD Anderson [Xconomy] In the video, DePinho said he will now focus on national cancer research efforts. “I need to focus on the cancer moonshot,” he said. “I need to be more intensely engaged with the national cancer and health policy landscape.”
Ronald DePinho, embattled chief of MD Anderson Cancer Center, resigns [STAT] In an unusually forthcoming statement posted on MD Anderson’s website, DePinho appeared to take responsibility for the turmoil at the institution and the negative publicly it has attracted in recent months.
Cancer researcher has dodged accusations for decades (and has a new correction) [Retraction Watch] Croce did not respond to questions about the new correction, but he has previously denied plagiarism allegations, explaining that OSU had also cleared him of a plagiarism charge from an anonymous whistleblower (a claim we couldn’t verify).
Years of Ethics Charges, but Star Cancer Researcher Gets a Pass [NY Times] Dr. Carlo Croce was repeatedly cleared by Ohio State University, which reaped millions from his grants. Now, he faces new whistle-blower accusations.